Science and Technology Science and Technology
Tue, April 7, 2009
Mon, April 6, 2009
Sun, April 5, 2009

Active Biotech: Active Biotech: Notice of Annual General Meeting of Shareholders


Published on 2009-04-06 10:29:30, Last Modified on 2009-04-06 10:30:00 - Market Wire
  Print publication without navigation


LUND, SWEDEN--(Marketwire - April 6, 2009) -


The Board of Directors of Active Biotech AB (publ) has today issued a notification of the Annual General Meeting, which is to take place at 5 p.m. on Thursday, May 7, 2009, at the Company's premises at Scheelevägen 22 in Lund, Sweden.

Please see the attached notification, which is being published on April 9 in Svenska Dagbladet and Post- och Inrikes Tidningar.

 Lund, April 6, 2009 ACTIVE BIOTECH AB (PUBL) THE BOARD OF DIRECTORS 

About Active Biotech

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phases are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, and ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDexTM for RA.

 Active Biotech AB P.O. Box 724, SE-220 07 Lund Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00 

Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication on April 6, 2009, at 8:30 a.m.


This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Active Biotech AB Notice of Annual General Meeting of Shareholders: [ http://hugin.info/1002/R/1303521/298667.pdf ]


Copyright © Hugin AS 2009. All rights reserved.